IL-GLOBAL-DAIRY
26.7.2021 11:02:07 CEST | Business Wire | Press release
A first-of-its-kind Pathways to Dairy Net Zero initiative is being developed to accelerate climate change action throughout the global dairy sector. Announced today at the United Nations (UN) Food Systems Pre-Summit, the climate effort will be unlike any other in agriculture in terms of size, breadth, and scope.
“The global dairy sector is creating this ground-breaking initiative to help speed climate action already underway, while continuing to provide livelihoods for a billion people and important nutrition for six billion people,” said Donald Moore, Executive Director at the Global Dairy Platform.
A multi-stakeholder group of organizations, including the global dairy sector and representatives from the scientific and research communities, are working together to develop methodologies, tools and pathways that work for every dairy system. Pathways to Dairy Net Zero will officially launch during the UN Food Systems Summit in September and aims to generate commitments at the UN Climate Change Conference, COP26, in November.
New research to guide the initiative
Research is underway to identify where positive climate change action is possible across all dairy production systems and regions throughout the world. The study is being conducted by the Global Research Alliance on Agricultural Greenhouse Gases (GRA), the UN Food and Agriculture Organisation, Scotland’s Rural College and the New Zealand Agricultural Greenhouse Gas Research Centre. Preliminary findings include:
- Positive change is possible across all dairy systems and regions. Although there is a wide variety of production systems globally, there are opportunities for all to reduce greenhouse gas emission (GHG) intensity.1
- Collaboration is needed to reduce dairy’s emissions. Many climate, poverty, and malnutrition challenges can be addressed through adoption of best practices in similar dairy systems.2
- Reducing methane may be key to fast results. Methane, a primary GHG produced by ruminant livestock, is short-lived. As a result, more reductions in methane would have a more immediate effect on warming.3
- Dairy already has the means to reduce a significant proportion of emissions. 4 Initial evidence suggests emissions can be reduced up to 40 percent in some systems by improving productivity and resource use efficiency.
- Defining terminologies and targets will focus efforts to achieve the best results. As indicated in the Intergovernmental Panel on Climate Change (IPCC) Special Report: Global Warming of 1.5°C, dairy’s carbon dioxide emissions need to strive to Net Zero, but its methane reduction can range from 24-47 percent, and its nitrous oxide reduction can be 26 percent.5
“Our initial analysis suggests that wider use of existing GHG mitigation technologies will make an important impact in reducing dairy’s emissions in the short term, while the development of new innovations takes place,” said Hayden Montgomery, Special Representative of GRA. “This initiative may ultimately act as a blueprint for other livestock sectors,” he added.
For more information about Pathways to Dairy Net Zero , visit: www.GlobalDairyPlatform.com/PathwaysToDairyNetZero .
You can register here for the UN Food Systems Pre-Summit affiliated session “Raising the climate ambition for the agriculture sector: An approach from dairy” on Monday, July 26, at 19:30 CEST.
References:
- Food and Agriculture Organization of the United Nations (FAO). 2010. Greenhouse Gas Emissions from the Dairy Sector: A Life Cycle Assessment. Available at: http://www.fao.org/3/k7930e/k7930e00.pdf [Accessed July 2021].
- Food and Agriculture Organization of the United Nations (FAO). 2019. Climate change and the global dairy cattle sector: The role of the dairy sector in a low‐carbon future. Available at: http://www.fao.org/3/CA2929EN/ca2929en.pdf [Accessed July 2021].
- UN Environment Programme. 2021. Global Methane Assessment: Benefits and Costs of Mitigating Methane Emissions. Available at: https://www.unep.org/resources/report/global-methane-assessment-benefits-and-costs-mitigating-methane-emissions [Accessed July 2021].
- Gerber PJ, Steinfeld H, Henderson B, et al. 2013. Tackling climate change through livestock – A global assessment of emissions and mitigation opportunities. Food and Agriculture Organization of the United Nations (FAO), Rome. Available at: http://www.fao.org/3/i3437e/i3437e.pdf [Accessed July 2021].
- The Intergovernmental Panel on Climate Change (IPCC). 2018. Global warming of 1.5°C. An IPCC Special Report on the impacts of global warming of 1.5°C above pre-industrial levels and related global greenhouse gas emission pathways, in the context of strengthening the global response to the threat of climate change, sustainable development, and efforts to eradicate poverty. Available at: https://www.ipcc.ch/site/assets/uploads/sites/2/2019/06/SR15_Full_Report_Low_Res.pdf [Accessed July 2021].
About Pathways to Dairy Net Zero
This is a vibrant, growing movement, the first of its kind in the world. It brings together dairy production systems of every size and type, as well as organizations throughout the dairy supply chain. Collaborators include Global Dairy Platform, International Dairy Federation, Sustainable Agriculture Initiative Platform, International Livestock Research Institute, Dairy Sustainability Framework and IFCN Dairy Research Network. The Global Research Alliance on Agricultural Greenhouse Gases is a knowledge partner.
www.GlobalDairyPlatform.com/PathwaysToDairyNetZero
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005299/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
